# A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC

> **NCT04286958** · PHASE2 · UNKNOWN · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04286958
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-22
- **Primary completion:** 2022-12-22
- **Final completion:** 2023-03-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04286958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04286958, "A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04286958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*